![]()
|
|
||||||||
J. Biol. Chem., Vol. 282, Issue 20, 15187-15196, May 18, 2007
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
9
1 Directly Binds to Vascular Endothelial Growth Factor (VEGF)-A and Contributes to VEGF-A-induced Angiogenesis*
1




2
From the
Lung Biology Center, University of California, San Francisco, California 94143-2922 and
Thoracic Disease Research Unit, Mayo Clinic College of Medicine, Rochester, Minnesota 55905
Vascular endothelial growth factor A (VEGF-A) is a potent inducer of angiogenesis. We now show that VEGF-A-induced adhesion and migration of human endothelial cells are dependent on the integrin
9
1 and that VEGF-A is a direct ligand for this integrin. Adhesion and migration of these cells on the 165 and 121 isoforms of VEGF-A depend on cooperative input from
9
1 and the cognate receptor for VEGF-A, VEGF receptor 2 (VEGF-R2). Unlike
3
1or
v
3 integrins,
9
1 was also found to bind the 121 isoform of VEGF-A. This interaction appears to be biologically significant, because
9
1-blocking antibody dramatically and specifically inhibited angiogenesis induced by VEGF-A165 or -121. Together with our previous findings that
9
1 directly binds to VEGF-C and -D and contributes to lymphangiogenesis, these results identify the integrin
9
1 as a potential pharmacotherapeutic target for inhibition of pathogenic angiogenesis and lymphangiogenesis.
Received for publication, October 2, 2006 , and in revised form, February 22, 2007.
* This work was supported by a Mayo Foundation scholarship (to N. E. V.), American Lung Association Research Grant RG-1018-N (to N. E. V.), and by NHLBI Grant R01 HL64353 from National Institutes of Health (to D. S.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
1 To whom correspondence may be addressed: Thoracic Disease Research Unit, Mayo Clinic College of Medicine, 200 First St. SW, Rochester, MN 55905. Tel.: 507-284-2957; Fax: 507-284-4521; E-mail: vlahakis.nicholas{at}mayo.edu.
2 To whom correspondence may be addressed: Lung Biology Center, University of California, P. O. Box 2922, San Francisco, CA 94143-2922. Tel.: 415-514-4269; Fax: 415-514-4278; E-mail: dean.sheppard{at}ucsf.edu.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
A. Caporali, E. Pani, A. J.G. Horrevoets, N. Kraenkel, A. Oikawa, G. B. Sala-Newby, M. Meloni, B. Cristofaro, G. Graiani, A. S. Leroyer, et al. Neurotrophin p75 Receptor (p75NTR) Promotes Endothelial Cell Apoptosis and Inhibits Angiogenesis: Implications for Diabetes-Induced Impaired Neovascularization in Ischemic Limb Muscles Circ. Res., July 18, 2008; 103(2): e15 - e26. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. E. Pegg Spermidine/spermine-N1-acetyltransferase: a key metabolic regulator Am J Physiol Endocrinol Metab, June 1, 2008; 294(6): E995 - E1010. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Serini, L. Napione, M. Arese, and F. Bussolino Besides adhesion: new perspectives of integrin functions in angiogenesis Cardiovasc Res, May 1, 2008; 78(2): 213 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Staniszewska, I. K. Sariyer, S. Lecht, M. C. Brown, E. M. Walsh, G. P. Tuszynski, M. Safak, P. Lazarovici, and C. Marcinkiewicz Integrin {alpha}9{beta}1 is a receptor for nerve growth factor and other neurotrophins J. Cell Sci., February 15, 2008; 121(4): 504 - 513. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |